Disease Diagnosis TRIZ Cases

Compact passively Q-switched frequency-doubled laser pulses generate transient vapor nanobubbles for fast, noninvasive malaria detection in field conditions.

Combining serum BDNF and CA125 with clinical data enables more reliable non-invasive endometriosis screening, diagnosis, and monitoring.

mRAGE biomarker screening improves sperm selection by detecting DNA fragmentation, oxidative stress, and mitochondrial dysfunction with less invasive testing.

A multi-marker panel detects glycocalyx disruption without destructive imaging, enabling earlier diagnosis and treatment guidance for vascular disease.

Urinary SAA2-derived peptide signatures enable non-invasive early detection and monitoring of systemic inflammation without blood draws.

Antibody-based detection of BIM-Bcl-2 and related heterodimers quantifies apoptosis pathway interactions to guide BH3 mimetic selection.

A buffer-releasing reagent cap and integrated LFA tube cut test-kit parts, waste, and packaging cost while keeping sample flow reliable.

Single-time-point Cystatin B and clusterin testing distinguishes progressive from stable CKD earlier than creatinine, SDMA, or biopsy.

CD73-deficient DP8α Tregs provide a non-invasive way to predict acute GvHD risk and guide treatment after allo-HSCT.

Blood S100A8 measurement enables earlier, less invasive endometriosis diagnosis and monitoring, especially in minimal and mild stages.

A calcium-free sperm motility test reveals CatSper functional defects, simplifying male infertility diagnosis and avoiding ineffective treatment.

A lateral flow hybrid peptide assay detects NMDA autoantibodies in blood for rapid, low-cost screening of chronic cerebral ischemia.

Saliva protein markers such as PK, MMP-9, and S100 proteins enable faster, more precise classification of mild versus advanced periodontitis.

CD5, CD14, and CD163 marker profiling separates pro-inflammatory dendritic cells from overlapping subsets and links their proportion to disease severity.

Engineered alpha-synuclein mutants suppress spontaneous aggregation while preserving seed-triggered detection for earlier, more accurate synucleinopathy assays.

Biofluid biomarkers such as GFAP, UCHL-1, Tau, and NF-L improve SAE diagnosis and help predict cognitive outcomes earlier.

B-cell exosome levels in blood help identify cancer patients more likely to benefit from immune checkpoint blockade with lower toxicity risk.

Gender-stratified IgG cutoff values and p-value-screened food panels improve psoriasis trigger-food testing by reducing false positives.

High-pH sample pretreatment disrupts enzyme-antibody interference, improving assay sensitivity for lysosomal storage disease monitoring.

Combining sIFNAR2 assessment with MRI dissemination markers improves multiple sclerosis diagnosis and prognosis accuracy.

A 3-11 serum biomarker panel replaces biopsy to diagnose NASH and stage hepatic fibrosis with lower invasiveness and cost.

Protein and peptide biomarker panels improve early preterm birth risk assessment with high sensitivity and specificity from maternal samples.

Serial urine biomarker tracking over 14 days improves prediction of renal recovery after AKI and helps target dialysis-related care.

Specific antibodies targeting the NT-proBNP HXLG epitope improve canine heart disease detection and prognosis through precise biomarker measurement.

A multi-protein antigen panel detects blood autoantibodies to distinguish Alzheimer's from SCD, MCI, and other dementias.

Flow cytometry isolates adipose and blood cell populations to quantify VEGFR thresholds for selecting targeted angiogenic obesity therapy.

A unified CPS formula combines tumor and inflammatory cell PD-L1 counts to cut pathologist workload and improve anti-PD eligibility decisions.

Combining GFAP with additional neuroactive biomarkers enables faster, objective detection of mild to moderate brain injury from CSF or serum.

Multiple enzymes on a polymer-linked nanoparticle boost lateral flow antigen detection sensitivity while simplifying conjugate fabrication.

A multi-biomarker TBI assay combines H-FABP, IL-10, GFAP, NF-L, and S100B to improve recovery outcome prediction for clinical use.